mva-bn-filo
Trade name: Mvabea
Vaccineexperimental
Clinical trial activity
21 trials · 28 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
14
Phase 3
7
Phase 4
0
Earliest trial started Sep 17, 2014 (NCT02240875)
Timeline
Indications
Studied for
- Filoviridae Infections · Phase 2
- Healthy Volunteers · Phase 3
- Hemorrhagic Disorders · Phase 1
- Hemorrhagic Fever, Ebola · Phase 3
- Hemorrhagic Fevers, Viral · Phase 2
- Immunologic Factors · Phase 2
- Infections · Phase 2
- Mononegavirales Infections · Phase 2
- Physiological Effects of Drugs · Phase 2
- RNA Virus Infections · Phase 2
- Vaccines · Phase 2
- Virus Diseases · Phase 2
Mechanism of action
- EbolavirusImmunity, active
Ebolavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva-bn filo
- mva-bn-filo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05284097 | Phase 2 | Sep 19, 2022 | Janssen Pharmaceutica NV, University of London, University of Sierra Leone |
| NCT04556526 | Phase 3 | Oct 5, 2020 | Center for Family Health Research (CFHR), Coalition for Epidemic Preparedness Innovations, Emory University, Janssen Pharmaceutica NV |
| NCT04228783 | Phase 3 | Feb 18, 2020 | Janssen Pharmaceutica NV |
| NCT04152486 | Phase 3 | Nov 14, 2019 | Coalition for Epidemic Preparedness Innovations, Epicentre, Government of the Democratic Republic of the Congo, Janssen Pharmaceutica NV, Medecins Sans Frontieres, Public Health England, University of London |
| NCT04028349 | Phase 2 | Jul 31, 2019 | Coalition for Epidemic Preparedness Innovations, Epicentre, Paris, France and Mbarara, Uganda, Janssen Pharmaceutica NV, Medical Research Council-UVRI Uganda Research Unit on AIDS |
| NCT03929757 | Phase 2 | Jul 12, 2019 | Janssen Pharmaceutica NV |
| NCT02876328 | Phase 2 | Mar 31, 2017 | Institut National de la Santé Et de la Recherche Médicale, France, National Institute of Allergy and Infectious Diseases (NIAID), Redemption Hospital, The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project, University of London, University of Sierra Leone |
| NCT02860650 | Phase 1 | Aug 29, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02661464 | Phase 3 | May 31, 2016 | Bavarian Nordic, Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02598388 | Phase 2 | Dec 10, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson, United States Army |
| NCT02564523 | Phase 2 | Nov 6, 2015 | EBOVAC2 Consortium, Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02509494 | Phase 3 | Sep 30, 2015 | Government of Sierra Leone, Grameen Foundation, Institut National de la Santé Et de la Recherche Médicale, France, Janssen Pharmaceutica NV, Johnson and Johnson, University of London, University of Oxford, University of Sierra Leone, World Vision of Ireland |
| NCT02543567 | Phase 3 | Sep 21, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02543268 | Phase 3 | Sep 1, 2015 | Crucell |
| NCT02416453 | Phase 2 | Jun 15, 2015 | Institut National de la Santé Et de la Recherche Médicale, France, Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02376400 | Phase 1 | Apr 1, 2015 | Crucell |
| NCT02376426 | Phase 1 | Mar 1, 2015 | Crucell |
| NCT02325050 | Phase 1 | Jan 8, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02313077 | Phase 1 | Dec 17, 2014 | Crucell |
| NCT02267109 | Phase 1 | Oct 1, 2014 | Leidos, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, Wellcome Trust |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (28)
28 organizations
Page 1 / 2